Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates

Bibliographic Information
Authors: Salem D.; El-Shenawy A.; Dahroug H.; Zaiton M.; Gamal D.; Diab M.
Journal: BMC Infectious Diseases
Publisher: BioMed Central Ltd
Publication Date: 28 April 2025
Volume / Issue: Volume 25 / Issue 1
Article No.: 622
ISSN: 14712334
DOI: 10.1186/s12879-025-10891-w
Scopus: View on Scopus
PubMed: 40295988
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Salem D., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt; El-Shenawy A., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt; Dahroug H., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt; Zaiton M., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt; Gamal D., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt; Diab M., Microbiology Department, Theodor Bilharz Research Institute (TBRI), P.O Box 12411, Postal Address: 30 Imbaba, Giza, Egypt
Abstract
Background: Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities. Ceftazidim/avibactam and ceftolozane/tazobactam have a potential role in treatment of multi-drug resistant phenotypes including carbapenem resistant P. aeruginosa. Therefore, we aimed to assess the in vitro antimicrobial activity of ceftazidime/avibactam and ceftolozane/tazobactam against carbapenem-resistant P. aeruginosa (CRPA) strains with different β-lactamase/carbapenemase genes. Methods: Sixty CRPA isolates identified from clinical samples were examined for antimicrobial susceptibility including ceftazidim/avibactam and ceftolozane/tazobactam by Vitek2 compact system, and carbapenemase production by modified carbapenem inactivation method (mCIM) test and carbapenemase producing genes by polymerase chain reaction (PCR). Results: Isolates were resistant to imipenem in 96.7% and meropenem in 88.3%. of isolates. Carbapenemase production by mCIM test was 70% compared to 73.3% by (PCR). Carbapenemase encoding genes blaNDM, blaVIM and blaOXA-48 were detected in 60%, 41.7% and 25% respectively while blaIMP and blaKPC weren’t identified in this study. Among CRPA, both ceftazidim/avibactam and ceftolozane/tazobactam; were sensitive in only 11.7% of the isolates. Resistance to ceftazidim/avibactam and ceftolozane/tazobactam in isolates owning blaNDM, blaVIM, blaOXA-48 and those having combined blaNDM, blaVIM and blaOXA-48 carbapenemase resistance genes were 97.2%, 92%, 100% and 100% respectively. Conclusion: Modified carbapenem inactivation method test gave satisfactory results and could be used as an alternative to expensive genotypic methods. Ceftazidim/avibactam and ceftolozane/tazobactam were unsuccessful against carbapenem resistant P. aeruginosa isolates carrying carbapenemase genes especially metallo-β lactamase genes. Therefore, it is essential to detect susceptibility patterns to newly introduced β-Lactam/β-Lactamase inhibitor combinations due to the emerging resistance to these therapeutics. © The Author(s) 2025.
Keywords
Carbapenem resistant P. aeruginosa; Ceftazidim/avibactam; Ceftolozane/tazobactam; Modified carbapenem inactivation method test; β-Lactam/β-Lactamase inhibitor combinations; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; amikacin; avibactam plus ceftazidime; aztreonam; carbapenemase; cefepime; ceftolozane plus tazobactam; ceftriaxone; ciprofloxacin; extended spectrum beta lactamase; gentamicin; imipenem; meropenem; metallo beta lactamase; piperacillin plus tazobactam; ticarcillin; timentin; tobramycin; antiinfective agent; avibactam, ceftazidime drug combination; azabicyclo derivative; bacterial protein; beta lactamase; carbapenem derivative; ceftolozane, tazobactam drug combination; cephalosporin derivative; antibiotic sensitivity; antimicrobial activity; Article; bacterial gene; bacterial strain; bacterium isolation; blaIMP gene; blaKPC gene; blaNDM gene; blaOXA 48 gene; blaVIM gene; carbapenem resistant Pseudomonas aeruginosa; genotype; in vitro study; minimum inhibitory concentration; nonhuman; polymerase chain reaction; drug combination; drug effect; genetics; human; isolation and purification; microbial sensitivity test; microbiology; multidrug resistance; Pseudomonas infection
Citation Information
Scopus Citations: 5
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
